Search

Displaying results 3991 - 4000 of 7284 in total
  1. Drug

    Enbezotinib

    go.drugbank.com/drugs/DB21565
    Investigational

    Enbezotinib has a monoisotopic molecular weight of 424.17 Da. … Enbezotinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Enbezotinib is a tyrosine kinase inhibitor.

  2. Target

    Serine/threonine-protein kinase mTOR

    go.drugbank.com/bio_entities/BE0002386
    TargetHumans

    The mTORC2 complex also phosphorylates various proteins involved in insulin signaling, such as FBXW8 and IGF2BP1 (By similarity). … The mTORC1 complex is inhibited in response to starvation and amino acid depletion (PubMed:12150925, PubMed:12150926, PubMed:24403073, PubMed:31695197).

    Synonyms: FKBP12-rapamycin complex-associated protein, FK506-binding protein 12-rapamycin complex-associated protein 1
  3. Drug

    Piflufolastat F 18

    go.drugbank.com/drugs/DB14805
    ApprovedInvestigational

    Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein expressed in many tissues that plays a role in folate uptake and neurotransmitter release - it is expressed in the prostate at … [A235169] As such, it has become a desirable target for PET imaging of prostate cancer tissues.

  4. Drug

    Moroctocog alfa

    go.drugbank.com/drugs/DB13999
    Approved

    is a fully recombinant factor VIII-Fc fusion protein which has an extended half-life compared with conventional factor VIII due to conjugation to the dimeric Fc domain of human immunoglobulin G1, a long-lived … Moroctocog alfa is produced through recombinant DNA technology and purification, resulting in a 1438 amino acid, 170 kDa protein [L41170].

  5. Target

    Proteasome subunit beta type-2

    go.drugbank.com/bio_entities/BE0002349
    TargetHumans

    Non-catalytic component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. … This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex)

    Synonyms: Multicatalytic endopeptidase complex subunit C7-I
  6. Drug

    Gemtuzumab ozogamicin

    go.drugbank.com/drugs/DB00056
    ApprovedInvestigational

    Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora … Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered

  7. Drug

    Difelikefalin

    go.drugbank.com/drugs/DB11938
    ApprovedInvestigational

    [A237620] Difelikefalin received FDA approval in August 2021 (under the brand name Korsuva), becoming the first FDA-approved therapy for patients with chronic kidney disease suffering from uremic pruritus … [A237610] These revelations led to the study of KOR agonists as a potential treatment option in patients suffering from pruritic conditions.

  8. Drug

    Gantenerumab

    go.drugbank.com/drugs/DB12034
    Investigational

    Gantenerumab binds to a unique Aβ epitope compared to other anti-Aβ antibodies and preferentially recognizes Aβ oligomers and fibrils over monomers.[A244720] … Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary

  9. Drug

    Trospium

    go.drugbank.com/drugs/DB00209
    ApprovedInvestigational

    [L6208] Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007.[L6211] … Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably.

  10. Drug

    Ethambutol

    go.drugbank.com/drugs/DB00330
    ApprovedInvestigational

    [A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_.[A229048] Ethambutol was granted FDA approval on 6 November 1967. … Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis.

    Synonyms: (+)-2,2'-(ethylenediimino)di-1-butanol